Published in AIDS on October 23, 2013
Peer Supported Collaborative Care Mental Health and Substance Use Disorder Care | NCT04601064
Socially-integrated transdisciplinary HIV prevention. AIDS Behav (2014) 1.18
Challenges in managing HIV in people who use drugs. Curr Opin Infect Dis (2015) 1.13
Response to: The relationship of physical performance with HIV disease and mortality: a cohort study. AIDS (2015) 1.08
Health behavior change models for HIV prevention and AIDS care: practical recommendations for a multi-level approach. J Acquir Immune Defic Syndr (2014) 0.97
The cascade of care in the Eastern European country of Georgia. HIV Med (2014) 0.92
The exposure assessment in current time study: implementation, feasibility, and acceptability of real-time data collection in a community cohort of illicit drug users. AIDS Res Treat (2013) 0.92
Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav (2015) 0.91
Improvements in the continuum of HIV care in an inner-city emergency department. AIDS (2016) 0.91
Exploring the social meaning of curing HIV: a qualitative study of people who inject drugs in Guangzhou, China. AIDS Res Hum Retroviruses (2015) 0.90
Individual and community factors associated with geographic clusters of poor HIV care retention and poor viral suppression. J Acquir Immune Defic Syndr (2015) 0.89
Incarceration of people living with HIV/AIDS: implications for treatment-as-prevention. Curr HIV/AIDS Rep (2014) 0.87
Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections. World J Hepatol (2016) 0.85
Using Mobile Health Technology to Improve HIV Care for Persons Living with HIV and Substance Abuse. AIDS Res Treat (2013) 0.84
Frailty, Inflammation, and Mortality Among Persons Aging With HIV Infection and Injection Drug Use. J Gerontol A Biol Sci Med Sci (2015) 0.83
HIV Care Continuum Among Men Who Have Sex With Men and Persons Who Inject Drugs in India: Barriers to Successful Engagement. Clin Infect Dis (2015) 0.83
Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq. Retrovirology (2014) 0.82
Increased Prevalence of Controlled Viremia and Decreased Rates of HIV Drug Resistance Among HIV-Positive People Who Use Illicit Drugs During a Community-wide Treatment-as-Prevention Initiative. Clin Infect Dis (2015) 0.80
Prospective CT screening for lung cancer in a high-risk population: HIV-positive smokers. J Thorac Oncol (2014) 0.78
Association between U.S. state AIDS Drug Assistance Program (ADAP) features and HIV antiretroviral therapy initiation, 2001-2009. PLoS One (2013) 0.78
Utilizing mHealth methods to identify patterns of high risk illicit drug use. Drug Alcohol Depend (2015) 0.77
The effect of bundling medication-assisted treatment for opioid addiction with mHealth: study protocol for a randomized clinical trial. Trials (2016) 0.77
Correlates of non-adherence to antiretroviral therapy in a cohort of HIV-positive drug users receiving antiretroviral therapy in Hanoi, Vietnam. Int J STD AIDS (2013) 0.76
Mobile technology intervention to improve care coordination between HIV and substance use treatment providers: development, training, and evaluation protocol. Addict Sci Clin Pract (2017) 0.75
The population impact of eliminating homelessness on HIV viral suppression among people who use drugs. AIDS (2016) 0.75
Explanatory Models and Illness Experience of People Living with HIV. AIDS Behav (2016) 0.75
Risk Prediction Tool for Medical Appointment Attendance Among HIV-Infected Persons with Unsuppressed Viremia. AIDS Patient Care STDS (2015) 0.75
A qualitative study of barriers to and facilitators of optimal engagement in care among PLWH and substance use/misuse. BMC Res Notes (2016) 0.75
Acceptability of a mobile health intervention to enhance HIV care coordination for patients with substance use disorders. Addict Sci Clin Pract (2017) 0.75
Uptake and Acceptability of Information and Communication Technology in a Community-Based Cohort of People Who Inject Drugs: Implications for Mobile Health Interventions. JMIR Mhealth Uhealth (2015) 0.75
Association between engagement in-care and mortality in HIV-positive persons: a cohort study. AIDS (2017) 0.75
The societal cost of heroin use disorder in the United States. PLoS One (2017) 0.75
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Retention in care: a challenge to survival with HIV infection. Clin Infect Dis (2007) 10.66
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants. NIDA Res Monogr (1991) 7.05
Vital signs: HIV prevention through care and treatment--United States. MMWR Morb Mortal Wkly Rep (2011) 6.90
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ (2009) 6.03
Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med (1999) 5.05
Missed visits and mortality among patients establishing initial outpatient HIV treatment. Clin Infect Dis (2009) 4.96
Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis (2003) 3.63
Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS (2001) 3.56
Entry and retention in medical care among HIV-diagnosed persons: a meta-analysis. AIDS (2010) 3.44
Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med (2006) 3.25
Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care (2005) 2.64
Racial disparities in HIV virologic failure: do missed visits matter? J Acquir Immune Defic Syndr (2009) 2.58
Dramatic decline in the HIV-1 RNA level over calendar time in a large urban HIV practice. Clin Infect Dis (2011) 2.49
Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. AIDS Care (2005) 2.42
Risk factors for delayed initiation of medical care after diagnosis of human immunodeficiency virus. Arch Intern Med (2008) 2.31
Predictors of outpatient medical appointment attendance among persons with HIV. AIDS Care (1999) 2.28
Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr (2012) 2.19
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Continuity of HIV-related medical care, New York City, 2005-2009: Do patients who initiate care stay in care? AIDS Patient Care STDS (2011) 1.87
Social and environmental predictors of plasma HIV RNA rebound among injection drug users treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2012) 1.80
Factors associated with the failure of HIV-positive persons to return for scheduled medical visits. HIV Clin Trials (2002) 1.65
Predictors identified for losses to follow-up among HIV-seropositive patients. J Clin Epidemiol (2006) 1.63
Social and structural determinants of HAART access and adherence among injection drug users. Int J Drug Policy (2009) 1.63
Sustained viral suppression in HIV-infected patients receiving antiretroviral therapy. JAMA (2012) 1.48
Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther (2007) 1.39
Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr (2009) 1.34
HIV infection among injection-drug users - 34 states, 2004-2007. MMWR Morb Mortal Wkly Rep (2009) 1.30
Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis (2011) 1.29
Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users. AIDS Care (2007) 1.20
Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics. J Community Health (2008) 0.94
Incidence and risk factors associated with lost to follow-up in a Belgian cohort of HIV-infected patients treated with highly active antiretroviral therapy. Int J STD AIDS (2010) 0.87
Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med (2009) 19.90
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science (2004) 8.22
Perioperative mortality and long-term survival following live kidney donation. JAMA (2010) 7.34
Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet (2007) 6.83
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr (2009) 3.76
Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis (2010) 3.72
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol (2007) 3.46
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Hepatitis C and progression of HIV disease. JAMA (2002) 3.15
HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet (2009) 3.03
Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology (2008) 3.00
Invasive cervical cancer risk among HIV-infected women: a North American multicohort collaboration prospective study. J Acquir Immune Defic Syndr (2013) 2.78
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology (2002) 2.71
Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol (2005) 2.64
Limited uptake of hepatitis C treatment among injection drug users. J Community Health (2008) 2.61
Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis (2012) 2.50
HIV incidence determination in the United States: a multiassay approach. J Infect Dis (2012) 2.47
Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS (2005) 2.34
High prevalence of liver fibrosis associated with HIV infection: a study in rural Rakai, Uganda. Antivir Ther (2011) 2.20
U.S. trends in antiretroviral therapy use, HIV RNA plasma viral loads, and CD4 T-lymphocyte cell counts among HIV-infected persons, 2000 to 2008. Ann Intern Med (2012) 2.18
Incorrect identification of recent HIV infection in adults in the United States using a limiting-antigen avidity assay. AIDS (2014) 2.18
Neighborhood poverty and injection cessation in a sample of injection drug users. Am J Epidemiol (2010) 2.07
KIR/HLA pleiotropism: protection against both HIV and opportunistic infections. PLoS Pathog (2006) 2.06
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America. Clin Infect Dis (2009) 2.05
Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis (2013) 1.94
Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS (2007) 1.92
The effect of HIV infection on longitudinal lung function decline among IDUs: a prospective cohort. AIDS (2013) 1.92
Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resource-limited settings? Clin Infect Dis (2013) 1.92
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA (2012) 1.88
Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med (2015) 1.86
Adherence to antiretroviral therapy and virologic suppression among HIV-infected persons receiving care in private clinics in Mumbai, India. Clin Infect Dis (2007) 1.83
High pregnancy intentions and missed opportunities for patient-provider communication about fertility in a South African cohort of HIV-positive women on antiretroviral therapy. AIDS Behav (2012) 1.83
HLA-Cw*04 and hepatitis C virus persistence. J Virol (2002) 1.83
Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Ann Intern Med (2013) 1.82
High prevalence of HIV, HIV/hepatitis C virus coinfection, and risk behaviors among injection drug users in Chennai, India: a cause for concern. J Acquir Immune Defic Syndr (2008) 1.81
Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis (2009) 1.80
Changes in blood-borne infection risk among injection drug users. J Infect Dis (2011) 1.74
APOBEC3B deletion and risk of HIV-1 acquisition. J Infect Dis (2009) 1.74
Predictive accuracy of the Veterans Aging Cohort Study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr (2013) 1.72
Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology (2006) 1.63
High HIV burden among people who inject drugs in 15 Indian cities. AIDS (2015) 1.60
Effects of human TRIM5alpha polymorphisms on antiretroviral function and susceptibility to human immunodeficiency virus infection. Virology (2006) 1.59
The effect of HIV infection on overdose mortality. AIDS (2005) 1.58
Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis (2010) 1.58
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol (2003) 1.52
Activation-induced cell death drives profound lung CD4(+) T-cell depletion in HIV-associated chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2014) 1.50
HIV incidence among injection drug users in Baltimore, Maryland (1988-2004). J Acquir Immune Defic Syndr (2006) 1.49
IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis (2010) 1.48
Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One (2013) 1.46
The relationship of physical performance with HIV disease and mortality. AIDS (2014) 1.46
The effect of neighborhood deprivation and residential relocation on long-term injection cessation among injection drug users (IDUs) in Baltimore, Maryland. Addiction (2011) 1.46
20 years into the Gambia Hepatitis Intervention Study: assessment of initial hypotheses and prospects for evaluation of protective effectiveness against liver cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.44
Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS (2004) 1.44
Provider and clinic-level correlates of deferring antiretroviral therapy for people who inject drugs: a survey of North American HIV providers. J Int AIDS Soc (2012) 1.44
The emerging HIV epidemic among men who have sex with men in Tamil Nadu, India: geographic diffusion and bisexual concurrency. AIDS Behav (2010) 1.43
Variations in sexual risks in drug users: emerging themes in a behavioral context. Curr HIV/AIDS Rep (2008) 1.43
Serum albumin as a prognostic indicator for HIV disease progression. AIDS Res Hum Retroviruses (2006) 1.42
Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users. AIDS (2012) 1.41
Discordance between CD4+ T-lymphocyte counts and percentages in HIV-infected persons with liver fibrosis. Clin Infect Dis (2012) 1.41
HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med (2013) 1.41
Non-fatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend (2005) 1.39
Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS Res Ther (2007) 1.39
NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol (2007) 1.36
Severity and correlates of liver disease in hepatitis C virus-infected injection drug users. Hepatology (2002) 1.35
The impact of HIV and high-risk behaviours on the wives of married men who have sex with men and injection drug users: implications for HIV prevention. J Int AIDS Soc (2010) 1.35
Effectiveness of highly active antiretroviral therapy among injection drug users with late-stage human immunodeficiency virus infection. Am J Epidemiol (2005) 1.34
Nonstructured treatment interruptions among injection drug users in Baltimore, MD. J Acquir Immune Defic Syndr (2009) 1.34
Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection. J Virol (2004) 1.34
Multistage genomewide association study identifies a locus at 1q41 associated with rate of HIV-1 disease progression to clinical AIDS. J Infect Dis (2010) 1.33